Mode
Text Size
Log in / Sign up
N/A N=22 Randomized Triple-blind Treatment

Restoration of Cognitive Function With TDCS and Training in Serious Mental Illness

Schizophrenia · Bipolar Disorder · Schizo Affective Disorder

Enrolled (actual)
22
Serious AEs
5.9%
Results posted
Dec 2022
Primary outcome: Primary: Working Memory Capacity Composite Score — .64; .70; .64; .72 Proportion of correct responses — p== .69

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
TDCS (Device); Sham Stimulation (Device); Cognitive Remediation (Behavioral); Bridging Group (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Dec 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Working Memory Capacity Composite Score
.64; .70; .64; .72; .63; .71 = .69
PRIMARY
Goal Maintenance Composite Score
3.34; 2.91; 2.78; 2.71; 2.60; 2.73 = .62
PRIMARY
Interference Control Composite Score
-.37; -.20; -.03; -.10; -.28; -.40 = .47
PRIMARY
The University of California San Diego Performance-Based Skills Assessment Total Score
78.33; 73.67; 82.00; 76.50; 78.36; 77.76 = .68
SECONDARY
First-Episode Social Functioning Scale Actual Performance Total Score
55.33; 55.17; 56.17; 56.50; 58.67; 53.50 = .81
SECONDARY
Novel N-Back Task D Prime Score
1.24; 1.29; 1.41; 1.34; 1.42; 1.33 = .79
SECONDARY
Complex Span Task Z-score
-.37; -.20; -.03; -.10; -.28; -.40 = .47
SECONDARY
MATRICS Consensus Cognitive Battery Processing Speed Subscale and the Reasoning and Problem-Solving Subscale T-score Average
44.58; 49.92; 43.50; 49.17; 44.15; 50.04 = .99
SECONDARY
Brief Psychiatric Rating Scale Total Score
34.00; 43.50; 32.00; 38.00; 31.83; 43.17 = .25
SECONDARY
Brief Negative Symptom Severity Scale Total Score
18.50; 25.17; 13.83; 21.17; 14.40; 21.00 = .98

Summary

Development of interventions that can effectively target and remediate the cognitive and functional impairment associated with serious mental illness is a treatment priority. Transcranial direct current stimulation (tDCS) is a safe, non-invasive neuromodulation technique that is capable of stimulating brain activity to facilitate learning. The primary objective of this study is to evaluate the pairing of two therapeutic techniques, cognitive remediation and tDCS, as a cognitively enhancing intervention. This study is designed to test the hypotheses that cognitive remediation paired with tDCS will be more efficacious than cognitive remediation delivered with sham stimulation and that intervention-induced cognitive change will be sustainable. To examine the incremental benefit of pairing tDCS with cognitive remediation, clinically stable outpatients between the ages of 18-65 who have a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder will be enrolled in a double-blind, double-baseline, sham-controlled clinical trial. Participants will be randomized in a 1:1 ratio to receive either tDCS or sham stimulation concurrent with working memory focused cognitive remediation. Training will be offered to participants in a small group format. Training will consist of 48 sessions, with 2-3 sessions scheduled in a week. Each training session will last 2 hours. One hour will be spent completing cognitive exercises that require working memory skills on a computer. TDCS or sham stimulation will be offered concurrent with the first 20 minutes of training with a StarStim neuromodulator. One mA of anodal stimulation will be applied to the left dorsal lateral prefrontal cortex and the cathodal electrode will be placed in the contralateral supraorbital position. Upon completion of working memory training, participants will transition to a 45-minute bridging group focus on application of cognitive skills in everyday life. To assess intervention-induced change, working memory, other aspects of cognition, functional capacity, community functioning, and symptom severity will be assessed pre- and post-intervention. Sustainability of intervention-induced change will be assessed with an assessment session 6 weeks post-intervention. Mixed effect, repeated measure ANOVAS will be used to analyze intervention-induced change.

Eligibility Criteria

Inclusion Criteria

  • Participants are eligible for the study if they have a diagnosis of schizophrenia, schizoaffective disorder, or bipolar I disorder and are clinically stable at the time of enrollment
  • defined as not severely depressed or acutely manic and no hospitalizations or antipsychotic medication changes in the four weeks prior to enrollment

Exclusion Criteria

  • Met criteria for a severe alcohol or substance use disorder in the last 6 months
  • Met criteria for a mild alcohol or substance use disorder in the last month
  • A history of head injury or neurological disease that has compromised cognitive functioning
  • Ability to speak English is not sufficient to understand study procedures
  • Diagnosis of learning disability, mental retardation, or pervasive developmental disorder
  • Diagnosis of a medical condition that is incompatible with tDCS procedures
  • Participant does not demonstrate understanding of study procedures during the consent process
  • A documented history of behavioral problems that prevent participation in a group intervention
  • Participated in a study of tDCS or cognitive remediation in the previous 12 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03208036). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search